we aimed to investigate the relation between body mass index (BMI) and N-Terminal pro Brain Natriuretic Peptide (NT-proBNP) level. Patients and methods: From a French regional survey for acute MI, we formed 739 triplets of patients (n=2217) with an acute MI, matched with respect to age, gender, and renal function (MDRD, modification of diet in renal disease), each classified for BMI groups as obese (BMI> 30 kg/m²), overweight (BMI 25-29.9 kg/m²) and normal (BMI 20-24.9 kg/m²). Blood samples were taken on admission to assess NT-proBNP levels.

Results: Among the 2217 participants, mean age was 68±12 years, 80% were male and MDRD was 75±26 ml/min/1.73m². Higher prevalence of CV risk factors (hypertension, diabetes and dyslipidemia) was found across the overweight and obese groups. Admission CRP levels were increased in obese patients. Clinical heart failure on admission and LVEF were similar for the 3 groups. When compared with normal BMI, levels of NT-proBNP dramatically decreased by about 20% in overweight and by 60% in obese patients (1046 vs 839 and 444 pg/ml, respectively, p<0.001). An inverse relationship between the propeptide values and BMI was found (r=0.20, p=0.0001). By multivariable linear regression, BMI was a predictor of logNT-proBNP level. One-Y CV mortality was similar for the 3 BMI groups (p=0.091). By multivariate logistic regression analysis, logNT-proBNP independently predicted 1-Y CV mortality in normal (OR95%CI): 2.24(1.29-3.89)) and overweight (OR95%CI): 6.11(2.75-13.60)) patients. However, in obese patients, the propeptide levels failed to retain its prognostic capacity (OR95%CI: 1.44(0.88-2.35)).

Conclusions: In this large contemporary non-selected cohort of MI patients, NT-proBNP levels were dramatically reduced in obese patients even matched for age, renal function and gender. Moreover, in obese patients with acute MI, the significance of the propeptide level as an independent prognostic factor remains to be determined.

017

Incidence, type and prognostic impact of bleeding complications with radial primary PCI of STEMI: The Pitié-Salpêtrière experience

Olivier Barthelemy (1), J. Silvain, Anne Bellemain-Appaix (1), F. Beygui, J.P. Collet (1), R. Choussat (1), Nicolas Vignolles(1), G. Montalescot (1), Anne Mercadier (2)

(1) CHU Pitié Salpêtrière, Département de Cardiologie Médicale, Paris Cedex 13, France
(2) CHU Pitié-Salpêtrière, Etablissement Français du Sang (Paris)

Aim: We evaluated the rates, types and prognostic impact of bleeding complications in all-comers presenting with STEMI treated with aggressive anti-thrombotic treatment and radial access for primary PCI.

Methods: Consecutive STEMI patients (n=695) were evaluated for bleeding complications using a web-based registry (e-PARIS). In-hospital bleeding complications were adjudicated using various definitions (TIMI, GUSTO, STEEPEL). In-hospital ischemic events were the composite of MI, stroke and recurrent ischemia leading to urgent revascularization.

Results: Mean age was 63±/14 years, 531 (76.4%) were male, 142 (20.4%) diabetic, 141 (20.3%) had known coronary disease. In this non-selected, high risk population, 5.2% had cardiogenic shock on admission, 3.7% had pre-hospital cardiac arrest, 49.4% had multivessel disease and in 45.2% the left anterior descending artery or left main was the culprit artery. Radial access (88%) was used as often as possible as well as abciximab (82%). Thrombolytic treatment and radial access for primary PCI.

Conclusions: Although bleeding rates vary a lot with the definitions used, major or minor bleedings strongly relate to 1-yr mortality after primary PCI and weigh at least as much as recurrent ischemic complications. The most frequent MB with radial primary PCI is GI bleeding.

018

Immediate and 12 month outcomes of interventional reperfusion strategy in acute ST elevation myocardial infarction at a developing country hospital.Compared to the west, can good results be achieved?

Salem Abdessalem, Rim Ben Rejeb, Sami Mourali, Rachid Mechmèche

Hospital la Rabta, cardiology, Tunisie, Tunisie

Background: Percutaneous coronary intervention (PCI) has been proven to be the treatment of choice in acute ST-elevation myocardial infarction (STEMI) in the whole world. There is limited adoption and a paucity of data on outcomes following PCI in developing countries.

The objective of this study was to describe the procedural and clinical outcomes of patients undergoing PCI for STEMI at a university hospital in Tunisia and make a comparison with outcomes from the West.

Methods: We conducted a retrospective cohort study at a tertiary care university hospital in Tunis, Tunisia. A total of 209 consecutive patients undergoing PCI between January 2005 and June 2007 were reviewed. cox proportional hazards models were constructed. The primary outcome was mortality: in-hospital, 30 days, and 12-month later.

Results: The mean patient’s TIMI score was 3.8±4.2 (10% were in cardiogenic shock). Procedural success was 75.5%. In-hospital, 30 days and 12 months mortality were respectively 5.3%, 6.7% et de 8.2%, comparing favorably with TIMI’s score predicted mortality and the published registries from developed countries. Multivariate predictors of in-hospital death included (hazards ratio, 95% confidence interval) age>70 years, multivessel disease and PCI failure. Multivariate predictors of 12 months death were kippil III-IV status at admission and PCI failure.

Conclusion: We conclude that, despite the logistic difficulties, excellent outcomes for acute interventional reperfusion strategy in STEMI can be achieved in a developing country, possibly similar to those seen in the West. There is a strong need for making the practice of PCI in STEMI more widespread in developing regions.

019

Aspirin Non Compliance is the Major cause of “Aspirin Resistance” in Patients undergoing Coronary Stenting

Thomas Cuisset (1), Corinne Frere (2), Jacques Quilici (3), Raphael Poyet (1), Laurent Bali (3), Pierre E Morange (4), Marie Christine Alessi (4), Jean Louis Bonnet (3)

(1) CHU Timone, Service de Cardiologie Interventionnelle, Marseille, France – (2) Inserm, U626, Faculté de Médecine, Laboratoire d’Hémato-

© Elsevier Masson SAS. All rights reserved.